Blackstone Inc
MRNS

Blackstone Inc’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Blackstone Inc’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,382
Closed -$439K – 668
2021
Q1 		$439K Buy
+28,382
New +$411K ﹤0.01% 389

Other funds holding MRNS

LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Blackstone Inc's MRNS Position: Q2 2021 in Review

Blackstone Inc sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2021, closing a stake of 28,382 shares — an estimated $439K sold.

Blackstone Inc first reported a position in MRNS in Q1 2021 and held it in 1 quarter. The position peaked at $439K in Q1 2021. 80 funds tracked by Wall St. Rank hold MRNS as of Q2 2021.

  • Blackstone Inc reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2021 after selling out during the quarter.
  • Blackstone Inc sold 28,382 Marinus Pharmaceuticals, Inc shares in Q2 2021, an estimated $439K.
  • Blackstone Inc first reported a position in Marinus Pharmaceuticals, Inc in Q1 2021 and held it in 1 quarter.
  • Blackstone Inc's Marinus Pharmaceuticals, Inc position peaked at $439K in Q1 2021.
  • 80 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2021.

Based on Blackstone Inc's 13F filing for Q2 2021, filed 16 Aug 2021.